glp-1 agonists receptor show promise in treating substance use disorders Potential Use of GLP-1 and
Description
While some ingredients show limited potential, the evidence remains nuanced and should be interpreted carefully
Individual results may vary
GLP-1/GIP Therapy Discontinuation: Why the How Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro) is weight regain after stopping therapy
GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d
The Global GLP-1 Receptor Agonists Obesity Drugs Market was valued at USD 9.96 Billion in 2024 and is expected to reach USD 33.12 Billion by 2032, growing at a CAGR of 16.20% (2025-2032).
